Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
Organization Praises FDA Approval of Risedronate Therapy
May 6th, 2000
The National Osteoporosis Foundation (NOF) commends the U.S. Food and Drug Administration (FDA) on its approval of Actonel (risedronate), a therapy for the prevention and treatment of osteoporosis. Sandra C. Raymond, NOF, said, "With approval of Actonel women now have another choice of therapy for this disabling disease. This therapy for the prevention and treatment of osteoporosis and its associated fractures will help at risk women remain active, strong, and independent throughout their lives. This can only happen if women past menopause talk to their physicians to evaluate their bone health and, if appropriate, take action." "Osteoporosis is a...
Source: Women's Health Weekly (2000-05-06)
|
